[go: up one dir, main page]

NO974972L - FremgangsmÕte for Õ hindre brystcancer - Google Patents

FremgangsmÕte for Õ hindre brystcancer

Info

Publication number
NO974972L
NO974972L NO974972A NO974972A NO974972L NO 974972 L NO974972 L NO 974972L NO 974972 A NO974972 A NO 974972A NO 974972 A NO974972 A NO 974972A NO 974972 L NO974972 L NO 974972L
Authority
NO
Norway
Prior art keywords
procedure
breast cancer
preventing breast
preventing
cancer
Prior art date
Application number
NO974972A
Other languages
English (en)
Other versions
NO322468B1 (no
NO974972D0 (no
Inventor
Frederic Jay Cohen
Joan Ellen Glusman
Ronald Keith Knickerbocker
Nikolaus Thomas Nickelsen
Teri Janine Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27268608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974972(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9624800.0A external-priority patent/GB9624800D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO974972D0 publication Critical patent/NO974972D0/no
Publication of NO974972L publication Critical patent/NO974972L/no
Publication of NO322468B1 publication Critical patent/NO322468B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19974972A 1996-10-30 1997-10-28 Anvendelse av raloksifen for primaer forhindring av ostrogenavhengig brystcancer hos post-menopausale kvinner NO322468B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2985096P 1996-10-30 1996-10-30
GBGB9624800.0A GB9624800D0 (en) 1996-11-29 1996-11-29 Methods of preventing breast cancer
US4026097P 1997-03-10 1997-03-10

Publications (3)

Publication Number Publication Date
NO974972D0 NO974972D0 (no) 1997-10-28
NO974972L true NO974972L (no) 1998-05-04
NO322468B1 NO322468B1 (no) 2006-10-09

Family

ID=27268608

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19974972A NO322468B1 (no) 1996-10-30 1997-10-28 Anvendelse av raloksifen for primaer forhindring av ostrogenavhengig brystcancer hos post-menopausale kvinner
NO974973A NO974973D0 (no) 1996-10-30 1997-10-28 Forbedringer vedrörende profylakse av brystcancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO974973A NO974973D0 (no) 1996-10-30 1997-10-28 Forbedringer vedrörende profylakse av brystcancer

Country Status (43)

Country Link
US (2) US6303634B1 (no)
EP (3) EP1369115B1 (no)
JP (2) JPH10147530A (no)
CN (2) CN1182591A (no)
AP (1) AP971A (no)
AR (2) AR013864A1 (no)
AT (2) ATE338551T1 (no)
AU (3) AU5005197A (no)
BE (2) BE1011382A5 (no)
BG (1) BG63841B1 (no)
BR (1) BR9712703A (no)
CA (2) CA2219070C (no)
CH (2) CH691847A5 (no)
CZ (2) CZ341297A3 (no)
DE (2) DE69736644T2 (no)
DK (2) DK0839532T3 (no)
EA (2) EA006083B1 (no)
EE (1) EE03663B1 (no)
ES (4) ES2135342B1 (no)
FR (2) FR2756490B1 (no)
GB (3) GB2318734B (no)
GE (1) GEP20032910B (no)
GR (2) GR970100409A (no)
HU (2) HUP9701777A3 (no)
IE (2) IE970773A1 (no)
IL (2) IL122026A0 (no)
IS (1) IS5035A (no)
IT (2) ITMI972434A1 (no)
LU (2) LU90158B1 (no)
LV (1) LV12353B (no)
MY (1) MY121623A (no)
NL (2) NL1007387C2 (no)
NO (2) NO322468B1 (no)
NZ (1) NZ329042A (no)
PT (2) PT1369115E (no)
RO (1) RO120813B1 (no)
SG (2) SG83672A1 (no)
SI (3) SI20107A (no)
SK (1) SK287047B6 (no)
TR (1) TR199900951T2 (no)
UA (1) UA46762C2 (no)
WO (2) WO1998018325A1 (no)
YU (1) YU42397A (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
FI982733A7 (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
DK1401446T3 (da) 2001-05-22 2005-05-23 Lilly Co Eli Tetrahydroquinolinderivater til inhiberingen af sygdomme forbundet med estrogenmangel eller med en urelgelmæssig fysiologisk reaktion til endogent estrogen
US20040225200A1 (en) * 2003-05-09 2004-11-11 Edmundson Catherine M. System and method of analyzing the health of a population
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN102973573B (zh) * 2012-11-28 2015-04-08 玉林师范学院 一种人乳腺癌细胞抑制剂及制备方法
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
CN116650484A (zh) * 2023-05-11 2023-08-29 南通大学 一种乳腺癌相关蛋白的抑制剂及其应用
WO2025099483A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Use for raloxifene for the treatment of hepatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms
ZA951497B (en) * 1994-03-02 1996-08-23 Lilly Co Eli Orally administerable pharmaceutical formulations
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
US5821254A (en) 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
RO121117B1 (ro) * 1996-03-26 2006-12-29 Eli Lilly And Company Compoziţie farmaceutică conţinând derivaţi de benzotiofen şi utilizarea acesteia

Also Published As

Publication number Publication date
WO1998018325A1 (en) 1998-05-07
HUP9701778A3 (en) 1999-06-28
CZ341197A3 (cs) 1998-05-13
AP9901494A0 (en) 1999-03-31
IS5035A (is) 1999-04-27
LU90157B1 (fr) 1998-06-02
GB2318734B (en) 1999-12-01
IL122026A0 (en) 1998-03-10
CA2219070A1 (en) 1998-04-30
FR2756490A1 (fr) 1998-06-05
IT1298470B1 (it) 2000-01-10
FR2756490B1 (fr) 2003-06-20
CA2219070C (en) 2007-12-18
HUP9701777A3 (en) 1999-07-28
EA200100716A1 (ru) 2002-06-27
GB9911557D0 (en) 1999-07-21
SG83672A1 (en) 2001-10-16
US20020019418A1 (en) 2002-02-14
ATE239475T1 (de) 2003-05-15
HK1010495A1 (en) 1999-06-25
DE69721692T2 (de) 2004-03-25
ITMI972433A1 (it) 1999-04-29
BG103369A (en) 2000-05-31
GR1003189B (el) 1999-09-01
NL1007386C2 (nl) 1998-05-14
CZ300261B6 (cs) 2009-04-01
AP971A (en) 2001-05-30
CZ341297A3 (cs) 1998-05-13
NO322468B1 (no) 2006-10-09
GB9722801D0 (en) 1997-12-24
EP1369115B1 (en) 2006-09-06
EP0839532B1 (en) 2003-05-07
CA2219377A1 (en) 1998-04-30
DK1369115T3 (da) 2007-01-02
NO974973D0 (no) 1997-10-28
DE69736644T2 (de) 2007-10-25
UA46762C2 (uk) 2002-06-17
AU5005197A (en) 1998-05-22
IE970773A1 (en) 2000-02-09
MX9708341A (es) 1998-08-30
SI0839532T1 (en) 2003-10-31
GB2318734A (en) 1998-05-06
GB2318733A (en) 1998-05-06
BE1011381A5 (fr) 1999-08-03
GEP20032910B (en) 2003-03-25
JPH10147529A (ja) 1998-06-02
CH693820A5 (fr) 2004-02-27
AU731388B2 (en) 2001-03-29
LV12353B (en) 2000-02-20
US6303634B1 (en) 2001-10-16
SK287047B6 (sk) 2009-10-07
EA002054B1 (ru) 2001-12-24
EE9900162A (et) 1999-12-15
IL122025A (en) 2003-01-12
LV12353A (lv) 1999-10-20
NZ329042A (en) 1999-08-30
NL1007387C2 (nl) 1998-05-14
GR970100409A (el) 1998-06-30
EP0839533A1 (en) 1998-05-06
CH691847A5 (fr) 2001-11-15
ES2135342B1 (es) 2000-05-16
DE69736644D1 (de) 2006-10-19
HU9701777D0 (en) 1997-12-29
HU9701778D0 (en) 1997-12-29
IL122025A0 (en) 1998-03-10
HUP9701777A2 (hu) 1999-06-28
SI20107A (sl) 2000-06-30
NO974972D0 (no) 1997-10-28
ES2197312T3 (es) 2004-01-01
HUP9701778A2 (hu) 1999-01-28
GB9722796D0 (en) 1997-12-24
ITMI972434A1 (it) 1999-04-29
DK0839532T3 (da) 2003-08-25
FR2755014A1 (fr) 1998-04-30
YU42397A (sh) 2000-10-30
EE03663B1 (et) 2002-04-15
CN1182590A (zh) 1998-05-27
EA199900431A1 (ru) 1999-10-28
SG72765A1 (en) 2000-05-23
WO1998018449A1 (en) 1998-05-07
RO120813B1 (ro) 2006-08-30
SK55999A3 (en) 2000-06-12
ES2271476T3 (es) 2007-04-16
BG63841B1 (bg) 2003-03-31
EP1369115A1 (en) 2003-12-10
IE970772A1 (en) 2000-02-09
PT1369115E (pt) 2006-12-29
ES2135342A1 (es) 1999-10-16
ATE338551T1 (de) 2006-09-15
AR010538A1 (es) 2000-06-28
MY121623A (en) 2006-02-28
CN1182591A (zh) 1998-05-27
DE69721692D1 (de) 2003-06-12
SI1369115T1 (sl) 2006-12-31
AR013864A1 (es) 2001-01-31
PT839532E (pt) 2003-09-30
AU5005697A (en) 1998-05-22
EA006083B1 (ru) 2005-08-25
FR2755014B1 (fr) 1999-02-05
ES2135343A1 (es) 1999-10-16
LU90158B1 (fr) 1998-06-02
MX9708340A (es) 1998-08-30
BR9712703A (pt) 1999-10-26
JPH10147530A (ja) 1998-06-02
TR199900951T2 (xx) 1999-07-21
AU4364897A (en) 1998-05-07
BE1011382A5 (fr) 1999-08-03
AU4364797A (en) 1998-05-07
EP0839532A1 (en) 1998-05-06
GR970100408A (el) 1998-06-30

Similar Documents

Publication Publication Date Title
NO974972L (no) FremgangsmÕte for Õ hindre brystcancer
ITMI990375A1 (it) Trattamento del cancro co epotiloni
DK0804910T3 (da) Brystprotese
FI972484L (fi) Karsinooman hoito
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
FI960658L (fi) Uudet bis-naftalimidit syövän hoitamiseksi
IDP000008233A (id) Metode pencegahan kanker payudara
NO20005148L (no) FremgangsmÕte for Õ fremstille 4-substituerte-1H-indol-3- glyoksamider
FI970717A7 (fi) Menetelmät kohtusyövän inhiboimiseksi
GB9804361D0 (en) Cancer treatment
FR2757043B1 (fr) Prothese mammaire
EP1232176A4 (en) Tumour suppressor factor
KR970050669U (ko) 개량 브래지어
GB9624800D0 (en) Methods of preventing breast cancer
GB9903035D0 (en) Treating cancer
ZA992858B (en) Methods of preventing breast cancer.
GB2334579B (en) Treating cancer
BR9700778A (pt) Métodos de inibição de tumores do cólon
NO964791D0 (no) Ammeanordning
FIU960293U0 (fi) Rinnanlämmitin
TH9701004359B (th) วิธีการป้องกันมะเร็งเต้านม
IL124500A0 (en) Emulsions for cancer treatment
GB9802420D0 (en) Skin cancer alleviator
GB9820000D0 (en) Cancer treatment
GB9818023D0 (en) Cancer treatment

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees